Gene-delivery Technology

Cystic fibrosis patient receives first-of-its-kind gene transfer

Published in Gene Therapy Weekly, May 9th, 2002

Copernicus Therapeutics, Inc., University Hospitals of Cleveland (UHC), Case Western Reserve University (CWRU) School of Medicine, and Cystic Fibrosis Foundation Therapeutics Inc., (CFFTI), a nonprofit affiliate of the Cystic Fibrosis Foundation, announced that the first person in a 12 patient study has received a first-of- its-kind nonviral gene transfer vector in an effort to develop gene therapy for cystic fibrosis (CF).

This study, being led by Dr. Michael Konstan, aims to use gene transfer technologies to provide a normal copy of the CF gene to correct the underlying defect. The mutations of this gene are the root cause of the disease. This trial is the first...

Want to see the full article?

Purchase this article for only $3.00

We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.

Welcome to NewsRx!

Learn more about a six-week, no-risk free trial of Gene Therapy Weekly

Source: Gene Therapy Weekly (2002-05-09)

NewsRx is Social

Top Medical Newsletters

Awards

Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005

Facts & Stats

NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.

Google 2010 PageRank: #2 Among Top Health News and Media Publications
Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry